Year: 2022

American Hotel Income Properties REIT LP Announces November 2022 U.S. Dollar Cash Distribution

Written by Customer Service on November 15, 2022. Posted in Dividend Reports And Estimates.

(numbers are in U.S. dollars unless otherwise indicated) VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) — American Hotel Income Properties REIT LP (“AHIP”) (TSX: HOT.UN, HOT.U, and HOT.DB.V) announces a U.S. dollar cash distribution of $0.015 per limited partnership unit (“Unit”) for November 2022, which is equivalent to U.S. dollar $0.18 per Unit on an annualized basis. The distribution will be paid on December 15, 2022 to unitholders of record at the close of business on November 30, 2022. AHIP intends to pay cash distributions on or about the 15th day of each month to the unitholders of record on the last business day of the preceding month. ABOUT AMERICAN HOTEL INCOME PROPERTIES REIT LP American Hotel Income Properties REIT LP (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB.V), or AHIP, is a limited partnership formed to...

Global Video Conferencing Market to Surpass Market Valuation of $13.18 Billion by 2028 | Hardware to Generate Over 47% Market Revenue

Written by Customer Service on November 15, 2022. Posted in Mergers And Acquisitions.

Global video conferencing market was valued at USD 6.25 billion in 2021, and it is expected to reach a value of USD 13.18 billion by 2028, at a CAGR of 11.25% over the forecast period (2022-2028). Westford, USA, Nov. 15, 2022 (GLOBE NEWSWIRE) — The proliferation of broadband and mobile Internet has spurred the growth of video conferencing market. The ability to connect with people face-to-face regardless of location has made video conferencing an attractive option for businesses and consumers alike. Video conferencing is one solution that is seeing a significant increase in demand. It allows businesses to hold meetings and collaborate remotely, which is essential for many businesses that are now operating remotely. There are many video conferencing solutions available on the market, each with different features and pricing plans....

SMG Industries, Inc. Reports Record Revenues of $19.3 Million for the Third Quarter and Significantly Expanding EBITDA

Written by Customer Service on November 15, 2022. Posted in Earnings Releases And Operating Results.

A Record $53.5 Million for the Nine Months Ended September 30, 2022 with Year to Date 2022 Revenues Up 55% from the Comparable Period in 2021 HOUSTON, TX, Nov. 15, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — SMG Industries, Inc. (the “Company”) (OTCQB:SMGI), a growth-oriented transportation services company focused on the domestic infrastructure logistics market, today reported financial results for its third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights: · Revenues increased approximately 31% to $19,331,484 for the three months ended September 30, 2022, compared to the three months ended September 30, 2021, · Revenues increased approximately 55% to $53,589,434 for the nine months ended September 30, 2022 compared to the year ago period,· Adjusted Gross Margins, a non-GAAP...

Interim report – Third quarter of 2022 – SP Group A/S

Written by Customer Service on November 15, 2022. Posted in Earnings Releases And Operating Results.

SP Group generated revenue of DKK 2,007.5 million in the 9M 2022 reporting period, a 9.2% improvement from DKK 1,838.8 million in 9M 2021. EBITDA was up by 11.9% to DKK 354.4 million from DKK 316.8 million last year, and profit before tax was up by 5.5% to DKK 202.9 million. FY 2022 guidance is maintained. SP Group expects FY 2022 revenue to grow by 5-15% for an EBITDA margin of 16-18% and an EBT margin of 9-12%. The Board of Directors of SP Group A/S has today considered and approved the interim report for 9M 2022. Highlights of the interim report:9M 2022 revenue was up by DKK 168.7 million to DKK 2,007.5 million, for a 9.2% year-on-year increase. Company acquisitions added DKK 48.1 million to consolidated revenue. Q3 revenue grew by 1.1%. Earnings before depreciation, amortisation and impairment losses (EBITDA) for the 9M 2022 period...

Global Hyaluronic Acid Market to Offer Revenue Opportunity of $16.93 Billion by 2028 | Hyaluronic Acid Dermal Filler to Generate More Than $7.13 billion Revenue

Written by Customer Service on November 15, 2022. Posted in Mergers And Acquisitions.

Global hyaluronic acid market was valued at USD 8.51 Billion in 2021, and it is expected to reach a value of USD 16.93 Billion by 2028, at a CAGR of 9.7% over the forecast period (2022–2028). Westford, USA, Nov. 15, 2022 (GLOBE NEWSWIRE) — The global market is expected to grow at a CAGR of 9.7% over the next seven years. The report, titled “Hyaluronic Acid Market – Opportunities and Challenges,” provides an in-depth analysis of the key drivers, trends, and challenges affecting the market. One of the primary drivers of growth in the market is the increasing prevalence of age-related diseases such as osteoarthritis and Alzheimer’s disease. The growth in these diseases has increased demand for hyaluronic acid products that can help improve symptoms such as pain, inflammation, and joint stiffness. Other factors...

Global Baby Food Market to Hit Sales of $99.75 Billion By 2028 | Clean Label, Organic and Gluten Free Products Gaining Traction of Parents

Written by Customer Service on November 15, 2022. Posted in Mergers And Acquisitions.

Global baby food market was valued at $74.57 Billion in 2021, and it is expected to reach a value of $99.75 Billion by 2028, at a CAGR of 4.39% over the forecast period (2022–2028). Westford, USA, Nov. 15, 2022 (GLOBE NEWSWIRE) — Global baby food market is growing at a rapid pace, with demand is expected to exceed $99.75 billion by 2028. According to the market research firm SkyQuest Technology, the demand for baby food has been driven by an increasing number of parents who are seeking high-quality and nutritious foods for their children. One of the key reasons behind this growth is the widespread adoption of breastfeeding by mothers. Breastfeeding provides babies with essential nutrients and antibodies that help promote healthy development. As a result, more parents are looking to introduce complementary foods into their children’s...

Medigus: Eventer Generated Record Revenues for the First Nine Months of 2022 Exceeding Full-Year 2021 Revenues

Written by Customer Service on November 15, 2022. Posted in Earnings Releases And Operating Results.

Revenues for the first nine months of 2022 were approx. $1.99 million Tel Aviv, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that its 46.21% owned subsidiary, Eventer Technologies Ltd. (“Eventer”), a software company engaged in the development of platforms enabling producers and venues to create virtual conferences and events with integrated smart ticketing solutions, achieved record financial results for the nine months ended September 30, 2022 (based on non-reviewed financial results provided to Medigus by Eventer). Eventer’s overall turnover from ticket sales for the nine months ended September 30, 2022 was approx. $49 million,...

InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

Written by Customer Service on November 15, 2022. Posted in Earnings Releases And Operating Results.

Eleventh consecutive quarter of sequential profitable revenue growth Annualized revenue run rate of $155 million Adjusted EBITDA1 run rate of $36 million Achieved Run Rate Net Profit of 12$ million Strong balance sheet with $93 million cash supporting future profitable growth NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”) is pleased to announce its financial and operating results for the third quarter ended September 30, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Third Quarter 2022 Key Financial & Operating HighlightsRecord revenue of $39 million (NIS 101 million), which represent a 63% growth than the third quarter...

PainReform Provides Business Update for the Third Quarter of 2022

Written by Customer Service on November 15, 2022. Posted in Earnings Releases And Operating Results.

Implements Technology Improvements Related to PRF-110 Manufacturing Process Ahead of Planned Phase 3 Clinical Trial in Bunionectomy TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the third quarter ended September 30, 2022. Ilan Hadar, Chief Executive Officer of Pain Reform, stated, “We are making steady headway towards commencing the Phase 3 U.S. clinical trial of PRF-110 for post-operative pain relief following bunionectomy surgery. Towards this end, with our CMO in the U.S.A, we implemented a number of enhancements to the manufacturing process. We encountered a requirement for some further work...

SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results

Written by Customer Service on November 15, 2022. Posted in Earnings Releases And Operating Results.

SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2022, and provided a company update. “We continue to utilize our capabilities and infrastructure to advance our development pipeline in immunotherapeutics directed at unmet medical needs in respiratory diseases and in gastrointestinal disease with our Clostridioides difficile (C. diff) program and have discovery programs in autoimmune disease and oncology. During the quarter we were able to show data that further validates our platform at targeted medical conferences....

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals